Photo: Stockinq / Shutterstock
News·
"We Decided Not to Delay": What Analysts Are Saying About Anthropic's IPO Prospectus
Anthropic goes public with a warning to investors that its technology poses existential risks / Photo: Samuel Boivin / Shutterstock.com
News·
Highlights from Anthropic's prospectus—one of the most anticipated IPOs of the year: online
Aardvark plans to agree on a new phase III trial design with the FDA and resume clinical development of ARD-101 next year / Photo: Unsplash / Julia Koblitz
Small Caps·
Aardvark sinks 65% on data from halted trial of hunger drug; FDA to allow new tests
Photo: X / NYSE
News·
Anthropic's IPO Prospectus Has Restored Faith in AI Stocks: The S&P 500 and Nasdaq Are Rising
News·
Unsteady Revenue Growth and 100 Pages of Risks: What Anthropic's IPO Prospectus Revealed
News·
Brazilian assets tumble after Lula's surprise win. Which equities could outperform?
Small Caps·
Staffing company Robert Half soars as Wall Street bets on a 'strong comeback'
News·
Luxury companies lost €250 billion in market value in 2026. Is it time to buy their stock?
Stock Screener
Buy
Sell
Go to section
Guru Portfolios

Track the investments of top funds and market legends

‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
Go to section
Small Caps
Merck will acquire Silence Therapeutics, which is developing a treatment for a rare blood cancer / Photo: www.silence-therapeutics.com
Small Caps·
Small caps last week: Deals for Silence and Braze, hair-loss pill success
Small Caps·
Biohaven soars 25% as drug moves closer to approval. Is there more upside?
Small Caps·
Defense stocks are sliding despite rising orders. What should investors do?
Small Caps·
Lycia IPO: Food allergy biotech cofounded by Nobel laureate debuts on the Nasdaq
Small Caps·
Motley Fool: Six next-generation tech stocks not to forget amid the Anthropic IPO
Go to section

Investment and Finance News